Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 22 Neoplasms 13 Colonic Neoplasms 10 Breast Neoplasms 10 Venous Thromboembolism 8 Prostatic Neoplasms 8 Multiple Myeloma 7 Recurrence 6 Polycythemia Vera 6 Carcinoma, Non-Small-Cell Lung 6 Thrombocythemia, Essential 4 Neoplasms, Plasma Cell 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Melanoma 3 Thrombosis 2 Sarcoma 2 Rectal Neoplasms 2 Primary Myelofibrosis 2 Pancreatic Neoplasms 2 Neoplastic Cells, Circulating 2 Neoplasms by Site 2 Myocardial Infarction 2 Lung Neoplasms 2 Intestinal Neoplasms 2 Intestinal Diseases 2 Inflammation 2 Gastrointestinal Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2

Interventions

Pemetrexed 9 Drug Therapy 9 osimertinib 7 Radiotherapy 6 Carboplatin 6 anlotinib 5 Radiosurgery 5 aflutinib 4 Gefitinib 4 Docetaxel 4 Cisplatin 4 tislelizumab 3 pembrolizumab 3 icotinib 3 Vinorelbine 3 Paclitaxel 3 Gemcitabine 3 Erlotinib Hydrochloride 3 toripalimab 2 dacomitinib 2 camrelizumab 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Liquid Biopsy 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × Aspirin × Clear all

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡